|
Real-world outcomes of first-line therapies for unresectable hepatocellular carcinoma in the United States. |
| |
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Guardant Health; Incyte; Lilly Japan; MSD; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma |
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Delta-Fly Pharma; Eisai; GlaxoSmithKline; Guardant Health; MSD; Nihon Medi-Physics; Novartis; Ono Yakuhin; Rakuten Medical Japan; Roche; SERVIER |
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst) |
| |
|
No Relationships to Disclose |
| |
|
Employment - Flatiron Health |
Stock and Other Ownership Interests - Flatiron Health; Roche |
| |
|
Employment - Bristol Myers Squibb |
Stock and Other Ownership Interests - Amgen Astellas BioPharma (I); Bristol Myers Squibb; Merck (I) |
Travel, Accommodations, Expenses - Bristol Myers Squibb |
| |
|
Employment - bristol myers squibb |
Stock and Other Ownership Interests - bristol myers squibb |
Travel, Accommodations, Expenses - bristol myers squibb |
| |
|
Employment - Nicklaus Children's Hospital |
Research Funding - Nicklaus Children's Hospital |
| |
|
Stock and Other Ownership Interests - Roche |
| |
|
No Relationships to Disclose |